- Home
- ROIV vs JLL Comparison
ROIV vs JLL Comparison
Compare ROIV & JLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | JLL |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | 48000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 16.8B |
| IPO Year | 2021 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ROIV | JLL |
|---|---|---|
| Price | $28.58 | $299.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $27.56 | ★ $362.50 |
| AVG Volume (30 Days) | ★ 6.3M | 689.4K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | N/A | ★ 16.40 |
| Revenue | $29,053,000.00 | ★ $26,115,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $385.85 | $6.83 |
| P/E Ratio | ★ N/A | $18.83 |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $8.73 | $194.36 |
| 52 Week High | $30.03 | $363.06 |
Technical Indicators
Market Signals| Indicator | ROIV | JLL |
|---|---|---|
| Relative Strength Index (RSI) | 63.29 | 38.96 |
| Support Level | $20.46 | $295.17 |
| Resistance Level | N/A | $309.50 |
| Average True Range (ATR) | 0.95 | 11.49 |
| MACD | -0.00 | 0.27 |
| Stochastic Oscillator | 66.80 | 41.08 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $74 billion for clients across diverse public and private real estate strategies.